Jacqueline Corrigan-Curay, acting director of the FDA's Center for Drug Evaluation and Research (CDER), announced her retirement effective July 2025. Her departure adds to a wave of senior staff exits at the FDA amid ongoing internal upheavals, including recent administrative leaves of other top officials such as Nicole Verdun at CBER. The turnover has raised concerns about the erosion of institutional expertise at the agency that oversees critical therapeutic product approvals. Corrigan-Curay's resignation follows turbulent leadership transitions marked by disputes within the Department of Health and Human Services, underscoring continued instability during a pivotal regulatory period.